Back to top
more

Clovis Oncology, Inc. (CLVS)

(Delayed Data from NSDQ)

$18.95 USD

18.95
1,240,915

+0.51 (2.77%)

Updated May 3, 2019 04:00 PM ET

After-Market: $18.96 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

What's in Store for Jounce (JNCE) This Earnings Season?

by Zacks Equity Research

Investors will look forward to pipeline updates when clinical-stage immunotherapy company, Jounce (JNCE), reports Q4 results.

What's in Store for Aimmune (AIMT) This Earnings Season?

by Zacks Equity Research

Aimmune (AIMT) is likely to provide an update on Palforzia's launch plans during Q4 investors' call. The drug gets an approval in January 2020 for the treatment of peanut allergy.

Is a Beat in the Cards for Clovis' (CLVS) Earnings in Q4?

by Zacks Equity Research

Clovis' (CLVS) sole marketed drug, Rubraca, is likely to have driven revenues in the fourth quarter.

Implied Volatility Surging for Clovis Oncology (CLVS) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Clovis Oncology (CLVS) stock based on the movements in the options market lately.

What's in Store for Corcept (CORT) This Earnings Season?

by Zacks Equity Research

During Corcept's (CORT) Q4 earnings call, investor focus will be on the sales uptake of its Cushing's syndrome drug Korlym and other pipeline updates.

Mylan (MYL) to Report Q4 Earnings: What's in the Offing?

by Zacks Equity Research

Investors will look forward to regular top and bottom-line numbers and updates on merger with Upjohn, when Mylan (MYL) reports Q4 results.

5 Drug/Biotech Stocks Likely to Beat Q4 Earnings Estimates

by Zacks Equity Research

Let us take a look at some drug/biotech stocks that are poised to beat on earnings in the fourth quarter.

Is a Beat in the Cards for Humana's (HUM) Earnings in Q4?

by Zacks Equity Research

Humana's (HUM) fourth-quarter results are likely to reflect lower membership, partly offset by higher revenues.

Acceleron (XLRN) Up on Success of PAH Drug in Phase II Study

by Zacks Equity Research

Acceleron (XLRN) stock surges as sotatercept meets primary and secondary endpoints in a phase II study in patients with pulmonary arterial hypertension.

Biotech Stock Roundup: Updates From HZNP & CLVS, BioNTech to Acquire Neon

by Zacks Equity Research

A low-key week for the biotech sector with a few pipeline and regulatory updates.

Clovis Rubraca sNDA for Prostate Cancer Gets Priority Review

by Zacks Equity Research

Clovis' (CLVS) sNDA seeking label expansion of Rubraca to include BRCA-mutant advance prostate cancer gets priority review from the FDA. Stock up.

Benjamin Rains headshot

Find Cheap Highly-Ranked Stocks Trading Under $10 for 2020

by Benjamin Rains

Here are 5 of the 36 highly-ranked stocks trading under $10 a share that made it through today's screen...

Implied Volatility Surging for Clovis (CLVS) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Clovis (CLVS) stock based on the movements in the options market lately.

FDA Accepts Immunomedics' BLA Refiling for Breast Cancer Drug

by Zacks Equity Research

The FDA accepts Immunomedics' (IMMU) BLA resubmission for sacituzumab govitecan to treat patients with metastatic triple-negative breast cancer, having received at least two prior therapies.

Corporate News for Dec 18, 2019

by Zacks Equity Research

Companies In The News Are: TGE, WOR, UL, CLVS

Implied Volatility Surging for Clovis (CLVS) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Clovis (CLVS) stock based on the movements in the options market lately.

Clovis (CLVS) Up 122.5% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Clovis (CLVS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Immunomedics Resubmits Application for Breast Cancer Drug

by Zacks Equity Research

Immunomedics (IMMU) resubmits BLA to the FDA for sacituzumab govitecan for the treatment of patients with metastatic triple-negative breast cancer, who have received at least two prior therapies.

Sweta Killa headshot

Biotech Tops in November: Best ETFs & Stocks

by Sweta Killa

The biotech space of the broad healthcare sector outperformed others in November, courtesy of a series of positive news including study results, regulatory backdrop and deal activities.

Clovis Oncology, Inc. (CLVS) Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Clovis Oncology, Inc. (CLVS).

Clovis (CLVS) Looks Good: Stock Adds 6.3% in Session

by Zacks Equity Research

Clovis (CLVS) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

Clovis (CLVS) Upgraded to Buy: Here's Why

by Zacks Equity Research

Clovis (CLVS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Sanghamitra Saha headshot

Healthcare Drives Wall Street: 5 Soaring ETFs & Stocks

by Sanghamitra Saha

Decent fundamentals and valuations as well as encouraging developments put these medical ETFs and stocks in focus.

Implied Volatility Surging for Clovis Oncology (CLVS) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Clovis Oncology (CLVS) stock based on the movements in the options market lately.

Clovis (CLVS) Q3 Earnings & Sales Beat Estimates, Shares Up

by Zacks Equity Research

Clovis (CLVS) reports encouraging third-quarter 2019 results. The company tightens guidance for product sales in 2019.